Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 1
1998 2
1999 2
2000 1
2003 1
2004 2
2006 1
2007 2
2009 4
2010 6
2011 5
2012 2
2013 4
2014 6
2015 5
2016 10
2017 6
2018 10
2019 11
2020 10
2021 16
2022 21
2023 11
2024 15
2025 19
2026 9

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

150 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean euh kj[au] (1 results)?
Artificial Intelligence-Powered Spatial Analysis of Tumor-Infiltrating Lymphocytes as Complementary Biomarker for Immune Checkpoint Inhibition in Non-Small-Cell Lung Cancer.
Park S, Ock CY, Kim H, Pereira S, Park S, Ma M, Choi S, Kim S, Shin S, Aum BJ, Paeng K, Yoo D, Cha H, Park S, Suh KJ, Jung HA, Kim SH, Kim YJ, Sun JM, Chung JH, Ahn JS, Ahn MJ, Lee JS, Park K, Song SY, Bang YJ, Choi YL, Mok TS, Lee SH. Park S, et al. Among authors: suh kj. J Clin Oncol. 2022 Jun 10;40(17):1916-1928. doi: 10.1200/JCO.21.02010. Epub 2022 Mar 10. J Clin Oncol. 2022. PMID: 35271299 Free PMC article.
Randomized, phase II trial to evaluate the efficacy and safety of atezolizumab plus capecitabine adjuvant therapy compared to capecitabine monotherapy for triple receptor-negative breast cancer with residual invasive cancer after neoadjuvant chemotherapy (MIRINAE trial, KCSG-BR18-21).
Lee J, Ahn HK, Lee KH, Jung KH, Park YH, Sim SH, Kim MH, Kim JH, Kim JH, Lee KE, Park KH, Bae J, Lee MH, Lim S, Kim HJ, Lee DW, Jeong JH, Kim JY, Ahn JS, Lee KS, Sohn J, Suh KJ, Cha YJ, Shin K, Kim SB, Chae H, Kim GM, Im SA, Park IH; Korean Cancer Study Group (KCSG) Breast Cancer Committee. Lee J, et al. Among authors: suh kj. BMC Cancer. 2025 Aug 9;25(1):1295. doi: 10.1186/s12885-025-14673-0. BMC Cancer. 2025. PMID: 40783751 Free PMC article. Clinical Trial.
Proliferation of Tumor-Related Regulatory T Cells in Circulation Dictates Efficacy of Chemoimmunotherapy in Triple-Negative Breast Cancer.
Jeon SH, Suh KJ, Jung S, Jeon M, Jang HC, Kim ES, Kim SH, Lee KH, Im SA, Kim MH, Sohn J, Jeong JH, Jung KH, Lee KE, Park YH, Kim HJ, Cho EK, Choi IS, Park SY, Kim M, Kim JH, Shin EC. Jeon SH, et al. Among authors: suh kj. Clin Cancer Res. 2025 Nov 3;31(21):4586-4597. doi: 10.1158/1078-0432.CCR-24-3283. Clin Cancer Res. 2025. PMID: 40833777 Clinical Trial.
VEGFR2 blockade overcomes acquired KRAS G12D inhibitor resistance driven by PI3Kγ activation.
Hwang SH, Bae M, Kim JW, Hyun SY, Kim KJ, Choe JH, Kim MJ, Park JW, Jeong SY, Choi S, Park W, Seo J, Chae H, Kang M, Jung EH, Suh KJ, Kim SH, Kim JW, Kim YJ, Kim JH, Park H, Aguirre AJ, Lee EA, Ku JL, Lee KW. Hwang SH, et al. Among authors: suh kj. bioRxiv [Preprint]. 2025 Sep 18:2025.09.16.676456. doi: 10.1101/2025.09.16.676456. bioRxiv. 2025. PMID: 41000780 Free PMC article. Preprint.
Genomic and transcriptomic analyses of residual invasive triple-negative breast cancer after neoadjuvant chemotherapy in the prospective MIRINAE trial (a randomized phase II trial of adjuvant atezolizumab plus capecitabine compared to capecitabine; KCSG-BR18-21).
Im SA, Park K, Koh J, Park C, Jung KH, Lee J, Ahn HK, Lee A, Sim SH, Kim MH, Kim JH, Kim JH, Lee KE, Park KH, Bae J, Lee MH, Lim S, Kim HJ, Lee DW, Jeong JH, Lee KS, Sohn J, Suh KJ, Kim JY, Cha YJ, Moon J, Ock CY, Kim SB, Shin K, Chae H, Kim GM, Lee KH, Park WY, Park YH, Park IH; Korean Cancer Study Group (KCSG) Breast Cancer Committee. Im SA, et al. Among authors: suh kj. ESMO Open. 2025 Oct;10(10):105804. doi: 10.1016/j.esmoop.2025.105804. Epub 2025 Sep 24. ESMO Open. 2025. PMID: 40997746 Free PMC article. Clinical Trial.
Reversibility of immune checkpoint inhibitor-induced hypothyroidism.
Seo J, Kim MJ, Kang M, Jung EH, Suh KJ, Kim JW, Kim SH, Kim JW, Kim YJ, Lee KW, Kim JH, Lee JS, Cho SW, Moon JH. Seo J, et al. Among authors: suh kj. Endocr Relat Cancer. 2025 Nov 25;32(11):e250138. doi: 10.1530/ERC-25-0138. Print 2025 Nov 1. Endocr Relat Cancer. 2025. PMID: 41200918
150 results